Sunyoung S. Lee, M.D., Ph.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
About Dr. Sunyoung S. Lee
Dr. Lee is a gastrointestinal medical oncologist and clinical faculty in the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center. He provides patient care at the MD Anderson main campus GI center and the West Houston clinic. Dr. Lee and his team have ranked in the top 1% nationally, recognized for excellent patient care and communication with patients and families as noted in CG-CAHPS. He is one of the main authors of the MD Anderson Manual of Medical Oncology on hepatocellular carcinoma (liver cancer and fibrolamellar liver cancer) and biliary tract cancers (bile duct and gallbladder cancer) and a PI and co-PI of clinical trials and research studies in the areas of liver, bile duct, pancreatic, and colorectal cancer. As a physician-scientist, he has expertise in genomic and imaging analyses and biological physics.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2018 | Massachusetts Institute of Technology, Cambridge, Massachusetts, US, Biological physics, Ph.D |
| 2015 | Massachusetts Institute of Technology, Cambridge, Massachusetts, US, Biological physics, M.S |
| 2013 | St. George's University School of Medicine, WI, GD, MD |
| 2007 | Seoul National University, Seoul, Chemical Engineering, Summa Cum Laude, BS |
Postgraduate Training
| 2016-2019 | Clinical Fellowship, Medical Oncology and Hematology, Roswell Park Comprehensive Cancer Center, Buffalo, New York |
| 2014-2016 | Clinical Residency, Internal Medicine, Mount Sinai School of Medicine, New York, New York |
| 2013-2014 | Clinical Internship, Internal Medicine, Mount Sinai School of Medicine, New York, New York |
Licenses & Certifications
| 2019 | Texas licensure |
| 2017 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019
Honors & Awards
| 2024 - Present | Top 1% and Perfect Score Patient Care Provider, MD Anderson Cancer Center, Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) |
| 2024 | Early-Career Clinical and Translational Research Award, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center |
| 2022 | Top 1% Patient Care Provider, MD Anderson Cancer Center, Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) |
| 2020 | Top 1% Patient Care Provider, MD Anderson Cancer Center, Consumer Assessment of Healthcare Providers and Systems (CAHPS) |
| 2020 | Career Enhancement Program Award, University of Texas MD Anderson SPORE in Hepatocellular Carcinoma |
| 2019 | Merit Award, ASCO Conquer Cancer Foundation |
| 2018 | Merit Award, ASCO Conquer Cancer Foundation |
| 2018 | Thomas F. Frawley Research Award, Roswell Park Comprehensive Cancer Center |
| 2018 | AACR Research Award in Honor of Cathy Whalen, AACR |
| 2017 | Vail Workshop (Methods in Clinical Cancer Research), ASCO/AACR |
| 2016 | ASH Travel Award, ASH Malignant Hematology |
| 2015 | Residency Peer Recognition Award, Mount Sinai School of Medicine |
| 2015 | Outstanding Research Award, Mount Sinai School of Medicine |
| 2015 | Finalist, American College of Physicians |
| 2014 | Presentation of Distinction, Mount Sinai School of Medicine |
| 2008 | Silver Medal, Samsung Electronics Research Competition, Seoul, South Korea |
| 2007 - 2008 | Hugh Hampton Young Memorial Fellowship, Massachusetts Insititute of Technology |
| 2007 | MIT Museum Research Exhibition, Massachusetts Insititute of Technology |
| 2004 | Korean Government Scholarship |
| 2002 | Graduation with Highest Honor, Seoul National University |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2020. Deep learning-based analysis of tissue segmentation in histopathology images of colorectal cancer. Conference. AACR, US.
- 2020. IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma. Conference. GI ASCO, US.
- 2020. Machine learning assisted prognostication model based on genomic expression in the tumor microenvironment of stage II and III breast cancer. Conference. AACR, US.
- 2019. The immune landscape of the tumor microenvironment predicts prognosis and DNA mutations in patients with lung adenocarcinoma. Invited. AACR. Chicago, IL, US.
- 2019. Modeling of prognostication and immune profiling, based on genomic analysis in the tumor microenvironment of pancreatic adenocarcinoma via machine learning. Invited. AACR. Atlanta, GA, US.
- 2019. Modeling of prognostication and differential genomic expression in the tumor microenvironment of clear cell renal cell carcinoma. Invited. GU ASCO. San Francisco, CA, US.
- 2019. Risk score and prognosis modeling based on mRNA expressivity in the tumor microenvironment of GI cancers. Invited. GI ASCO. San Francisco, CA, US.
- 2019. Machine learning-assisted prognostication based on genomic expression in the tumor microenvironment of estrogen receptor positive and HER2 negative breast cancer. Conference. ESMO, US.
- 2018. K-means algorithm-assisted clustering of patients and survival analysis, based on mRNA expressivity in the tumor microenvironment of hepatocellular carcinoma. Invited. AASLD. San Francisco, CA, US.
- 2018. Analysis of survival andmRNA expressivity in the tumor microenvironment of adenocarcinoma via K-means clustering algorithm. Invited. SITC. Washington, DC, US.
- 2018. Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. Conference. GI ASCO, US.
- 2018. Automated mapping and analysis of stromal cells in tumor microenvironment in pancreatic adenocarcinoma and cholangiocarcinoma. Conference. AACR, US.
- 2018. Automated analysis of mapping of stromal cells in tumor microenvironment in cholangiocarcinoma. Conference. Cholangiocarcinoma Foundation Annual Meeting, US.
- 2018. Automation of quantifying and mapping of stroma and malignant cells in pancreatic adenocarcinoma using deep learning. Conference. GI ASCO, US.
- 2015. Evolution of peripheral blood smear and lymph node histology in miliary tuberculosis. Conference. American Federation for Medical Research and Clinical and Translational Research, US.
- 2015. Rapid deposition of iron in the liver after transfusional support for management of refractory anemia in hemophagocytic lymphohistiocytosis. Conference. American College of Gastroenterology Annual Meeting, US.
- 2015. Delayed diagnosis of cholestatic drug-induced liver injury treated with corticosteroid for adrenal insufficiency secondary to miliary tuberculosis. Conference. American College of Gastroenterology Annual Meeting, US.
- 2015. Revisiting neoplastic and non-neoplastic dysplasia of cells of the myeloid lineage. Conference. American Society of Hematology (ASH) Hematologic Malignancies, US.
- 2015. Irony of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. Conference. Histiocyte Society Annual Meeting, US.
- 2015. Fulminant hepatic failure from hemophagocytic lymphohistiocytosis secondary to hepatosplenic T-cell lymphoma. Conference. American College of Physicians (ACP) National Competition, US.
- 2015. Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. Conference. Gordon Research Seminar - Cell Contact and Adhesion, US.
- 2015. Irony of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. Conference. Gordon Research Seminar – Phagocytes, US.
- 2015. Immune-mediated adalimumab-induced thrombocytopenia for the treatment of ulcerative colitis. Conference. Medical Society of the State of New York Resident/Fellow Symposium, US.
- 2015. Fulminant hepatic failure from hemophagocytic lymphohistiocytosis secondary to hepatosplenic T-cell lymphoma, mimicking Chinese herb-induced liver failure. Conference. American Federation for Medical Research and Clinical and Translational Research, US.
- 2015. Corticosteroid-induced morphological changes in cells of the myeloid lineage. Conference. American Federation for Medical Research and Clinical and Translational Research, US.
- 2008. Nano-scale mapping of VEGFR2 expressed with respect to fibronectin on substrates via functionalized force imaging. Conference. Biophysical Society Meeting, US.
- 2008. Beyond Bell’s Theorem: Reconciling theory, modeling, and experimental measurement of ligand-receptor unbinding forces. Conference. Biophysical Society Meeting, US.
- 2008. A Quantitative SPM Analysis of Cell Rolling. Conference. Biophysical Society Meeting, US.
- 2007. Chemomechanical mapping of cell surface receptors. Conference. Engineering Cell Biology Conference, US.
- 2007. Beyond Bell's Theorem: Reconciling theory, modeling, and experimental measurement of ligand-receptor unbinding forces. Conference. Biophysical Society Meeting, US.
- 2007. Seeing by feeling: Chemomechanical mapping of cell surfaces. Conference. Biophysical Society Meeting, US.
- 2006. Nanoscale imaging and binding kinetics of receptors on living and chemically fixed cell surfaces. Conference. Materials Research Society (MRS), US.
- 2006. Mechanical mapping of living cell surfaces. Conference. Materials Research Society (MRS), US.
- 2005. Chemomechanical mapping of living cell surfaces. Conference. Materials Research Society (MRS), US.
International Presentations
- 2020. Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy. Conference. ASCO, US.
- 2020. Risk score and prognostication modeling based on mRNA expressivity in the tumor microenvironment of hepatocellular carcinoma. Conference. ASCO, US.
- 2020. The role of ALBI and IGF-CTP score in refining prognostication of HCC. Conference. ASCO, US.
- 2020. Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. Conference. ASCO, US.
- 2020. Molecular validation of the 8th edition AJCC cancer staging system in patients with resected pancreatic cancer: Proposal of integrative translational staging system. Conference. ASCO, US.
- 2020. IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy. Conference. ASCO, US.
- 2020. Prognostication based on genomic expression in the tumor microenvironment of stage III ER+HER2- breast cancer. Conference. ASCO Clinical Immuno-Oncology Symposium, US.
- 2019. An independent validaton of a screening last using mass spectrometry for detection of hepatocellular carcinoma. Invited. ASCO. Altanta, US.
- 2019. Modeling of prognostication based on genomic expression in the tumor microenvironment of muscle invasive urothelial carcinoma via machine learning. Invited. ASCO Clinical Immuno-Oncology Symposium. San Francisco, US.
- 2015. Paraneoplastic orthostatic hypotension associated with acute myeloid leukemia with trisomy 8. Conference. American Federation for Medical Research and Clinical and Translational Research, US.
- 2015. Pseudo-Pelger-Huët anomaly and granulcytic dysplasia associated with human granulocytic anaplasmosis. Conference. American Federation for Medical Research and Clinical and Translational Research, US.
- 2015. Cholestatic drug-induced liver injury treated with corticosteroid in a patient with miliary tuberculosis and associated adrenal insufficiency. Conference. American Federation for Medical Research and Clinical and Translational Research, Chicago, US.
- 2008. Real time measurement of force and demonstration of associated intracellular machinery mediated by focal adhesions. Conference. Biophysical Society Meeting, US.
- 2006. Imaging mechanotransduction: Mapping cell surface receptor binding kinetics via functionalized force imaging. Conference. Seeing at the nano IV International Conference, US.
Grant & Contract Support
| Date: | 2025 - 2032 |
| Title: | A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants with Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation |
| Funding Source: | Servier Bio-Innovation LLC |
| Role: | PI |
| ID: | 2025-0514 | PID17729 |
| Date: | 2023 - 2030 |
| Title: | An Open-Label Phase 1b Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors |
| Funding Source: | Eisai Inc |
| Role: | Co-PI |
| ID: | 2022-0751 | E7386-J081-102 | PID14678 |
| Date: | 2022 - 2029 |
| Title: | A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma |
| Funding Source: | Tvardi Therapeutics, Inc |
| Role: | PI |
| ID: | 2022-0514 | PID14368 |
| Date: | 2022 - 2026 |
| Title: | A Phase 1b/2 Pressure Enabled Regional Immuno-Oncology Study of Hepatic Arterial Infusion of SD-101 with Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma |
| Funding Source: | TriSalus Life Sciences |
| Role: | PI |
| ID: | 2021-0863 | PID13391 |
| Date: | 2021 - 2026 |
| Title: | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA260872-01 |
| Date: | 2019 - 2024 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5P50CA217674-03 |
Selected Publications
Peer-Reviewed Articles
- Wang, X, Haro-Silerio, JI, Beaudry, FE, Borgida, A, Abbas-Aghababazadeh, F, Sahebi, NB, Wang, M, Fox, DA, Nuh, M, Hsiang, M, Bhamidipati, D, Kang, H, Cox, V, Ludmir, EB, Koay, EJ, Kwong, L, Quentin, K, Chatterjee, D, Chun, YS, Cao, HT, Meric-Bernstam, F, Hu, I, Dodd, A, Hamza, O, Hildebrand, M, Bucur, R, Hirschfield, GM, Vogel, A, O'Kane, GM, Gallinger, S, Haibe-Kains, B, Notta, F, Sapisochin, G, Knox, J, Javle, M, Lee, SS, Grant, RC. Clinicogenomic Characterization of Primary Sclerosing Cholangitis–Associated Biliary Tract Cancers. Clinical Cancer Research 32(2):363-374, 2026. e-Pub 2026. PMID: 41252561.
- De, BS, Dogra, P, Zaid, M, Elganainy, D, Sun, K, Amer, A, Wang, CX, Rooney, M, Chang, E, Kang, H, Wang, Z, Bhosale, PR, Odisio, BC, Newhook, TE, Tzeng, CD, Tran Cao, HS, Chun, YS, Vauthey, JN, Lee, SS, Kaseb, A, Raghav, KS, Javle, M, Minsky, B, Noticewala, SS, Holliday, EB, Smith, GL, Koong, AC, Das, P, Cristini, V, Ludmir, EB, Koay, EJ. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. npj Systems Biology and Applications 11(1), 2025. e-Pub 2025. PMID: 41387975.
- Verma, S, Hughes, A, Engel-Nitz, NM, Steiger, C, Parasuraman, S, Javle, M, Lee, SS, Saj, F, Blecker, M. Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary. Oncologist 30(11), 2025. e-Pub 2025. PMID: 41148042.
- Dharia, A, Xiao, L, Abraham, J, Saj, F, Eluri, M, Hu, Z, Lee, SS, Hassan, MM, Muddassir, S, Javle, M. Ethnic and socioeconomic disparities in survival outcomes among patients under 65 years with intrahepatic cholangiocarcinoma. Journal of Gastrointestinal Oncology 16(5):2138-2145, 2025. e-Pub 2025.
- Zhu Y, Solis Soto LM, Pant S, Vega EA, Vinuela E, Bozorgui B, Vauthey JN, Aguayo G, Wang Z, Lu W, Chen X, Mino B, Kakarala L, Dai J, Liu S, Wani KM, Lazar AJ, Carapeto F, Lee S, Wistuba I, Korkut A, Javle M, Kwong LN. Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance. Mod Pathol 38(11):100824, 2025. e-Pub 2025. PMID: 40541865.
- Jain AJ, Lendoire M, Haddad A, Tzeng CD, Boyev A, Maki H, Chun YS, Arvide EM, Lee S, Hu I, Pant S, Javle M, Tran Cao HS, Vauthey JN, Newhook TE. Improved Outcomes Following Resection of Perihilar Cholangiocarcinoma: A 27-Year Experience. Ann Surg Oncol 32(6):4352-4362, 2025. e-Pub 2025. PMID: 40000564.
- Verma, S, Lee, SS, Blecker, M, Hughes, A, Engel-Nitz, NM, Parasuraman, S, Javle, M. HSR25-160: Evaluating Patient Characteristics, Treatment Patterns, Clinical Outcomes, and Health Care Resource Use in Pemigatinib-Treated Cholangiocarcinoma (CCA) Patients: A Focus on Cancer of Unknown Primary. Journal of the National Comprehensive Cancer Network : JNCCN 23(35), 2025. e-Pub 2025. PMID: 40154361.
- Grewal K, Pant S, Hu I, Eluri M, An A, Higbie V, Huey R, Kasab A, Javle M, Lee S. CLO25-099: Lenvatinib With Pembrolizumab in Advanced Biliary Tract Cancer. J Natl Compr Canc Netw 23(3.5), 2025. e-Pub 2025. PMID: 40154395.
- Oh DY, Ikeda M, Lee CK, Rojas C, Hsu CH, Kim JW, Shen L, Furuse J, Park JO, Borad M, de Braud F, Bridgewater J, Lee SS, Moehler M, Audhuy F, Osada M, Sato M, Yoo C. Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial. Hepatology 81(3):823-836, 2025. e-Pub 2024. PMID: 38875119.
- DiPeri TP, Evans KW, Scott S, Zheng X, Varadarajan K, Kwong LN, Kahle M, Tran Cao HS, Tzeng CW, Vu T, Kim S, Su F, Raso MG, Rizvi Y, Zhao M, Wang H, Lee SS, Yap TA, Rodon J, Javle M, Meric-Bernstam F. Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clin Cancer Res 31(2):387-402, 2025. e-Pub 2025. PMID: 39513959.
- Yim SY, Lee SH, Kim JH, Lee SS, Kaseb AO, Lee JS. Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial". Clin Mol Hepatol 31(1):e84-e86, 2025. e-Pub 2025. PMID: 39370715.
- Lee SH, Yim SY, Kim JH, Lee SS, Kaseb AO, Lee JS. Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial". Clin Mol Hepatol 31(1):e81-e83, 2025. e-Pub 2025. PMID: 39370716.
- Hu ZI, Pavlick DC, Ross JS, Lee SS, Eluri M, Javle M. Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients. JCO Precis Oncol 9:e2400712, 2025. e-Pub 2025. PMID: 39772832.
- Lee SH, Yim SY, Kim JH, Lee SS, Kaseb AO, Wei P, Lee JS. Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". Clin Mol Hepatol 31(1):e110-e112, 2025. e-Pub 2025. PMID: 39355874.
- Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, Holliday EB, Smith GL, Noticewala SS, Nicholas S, Price TR, Martin-Paulpeter RM, Perles LA, Lee SS, Lee MS, Smaglo BG, Huey RW, Willis J, Zhao D, Cohen L, Taniguchi CM, Koay EJ, Katz MHG, Wolff RA, Das P, Pant S, Koong AC, Tang C. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol 42(32):3795-3805, 2024. e-Pub 2024. PMID: 39102622.
- Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO. Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma. J Immunother Precis Oncol 7(4):255-262, 2024. e-Pub 2024. PMID: 39524465.
- LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO. Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma. Oncology:1-8, 2024. e-Pub 2024. PMID: 39427654.
- Yim SY, Lee SH, Baek SW, Sohn B, Jeong YS, Kang SH, Park K, Park H, Lee SS, Kaseb AO, Park YN, Leem SH, Curran MA, Kim JH, Lee JS. Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial. Clin Mol Hepatol 30(4):807-823, 2024. e-Pub 2024. PMID: 39038962.
- De B, Dogra P, Zaid M, Elganainy D, Sun K, Amer AM, Wang C, Rooney MK, Chang E, Kang HC, Wang Z, Bhosale P, Odisio BC, Newhook TE, Tzeng CD, Cao HST, Chun YS, Vauthey JN, Lee SS, Kaseb A, Raghav K, Javle M, Minsky BD, Noticewala SS, Holliday EB, Smith GL, Koong AC, Das P, Cristini V, Ludmir EB, Koay EJ. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. medRxiv, 2024. e-Pub 2024. PMID: 39314943.
- Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark. e-Pub 2024. PMID: 39269823.
- Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America. Hepatology 80(1):87-101, 2024. e-Pub 2024. PMID: 38381705.
- Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey JN, Kaseb AO. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist 29(6):e803-e810, 2024. e-Pub 2024. PMID: 38159256.
- Shi C, De B, Tran Cao HS, Liu S, Florez MA, Kouzy R, Grippin AJ, Katz MHG, Tzeng CD, Ikoma N, Kim MP, Lee S, Willis J, Noticewala SS, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Ludmir EB, Koay EJ. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Cancer Med 13(12):e7434, 2024. e-Pub 2024. PMID: 38923407.
- Chang E, Wong FCL, Chasen BA, Erwin WD, Das P, Holliday EB, Koong AC, Ludmir EB, Minsky BD, Noticewala SS, Smith GL, Taniguchi CM, Rodriguez MJ, Beddar S, Martin-Paulpeter RM, Niedzielski JS, Sawakuchi GO, Schueler E, Perles LA, Xiao L, Szklaruk J, Park PC, Dasari AN, Kaseb AO, Kee BK, Lee SS, Overman MJ, Willis JA, Wolff RA, Tzeng CD, Vauthey JN, Koay EJ. Phase I Trial of SPECT-Guided Liver-Directed Radiotherapy for Patients with Low Functional Liver Volume. JNCI Cancer Spectr 8(3), 2024. e-Pub 2024. PMID: 38730548.
- Makawita S, Lee S, Kong E, Kwong LN, Abouelfetouh Z, Danner De Armas A, Xiao L, Murugesan K, Danziger N, Pavlick D, Korkut A, Ross JS, Javle M. Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol 8:e2300544, 2024. e-Pub 2024. PMID: 38547421.
- Jain AJ, Lendoire M, Boyev A, Newhook TE, Tzeng CD, Cao HST, Coronel E, Lee SS, Hu ZI, Javle M, Lee JH, Vauthey JN, Chun YS. ASO Visual Abstract: Revisiting the Malignant Masquerade at the Liver Hilum-Have We Made Progress?. Ann Surg Oncol. e-Pub 2024. PMID: 38383662.
- Jain AJ, Lendoire M, Boyev A, Newhook TE, Tzeng CD, Tran Cao HS, Coronel E, Lee SS, Hu ZI, Javle M, Lee JH, Vauthey JN, Chun YS. Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress?. Ann Surg Oncol. e-Pub 2024. PMID: 38282027.
- Haro-Silerio, JI, Fox, DA, Bhamidipati, D, Hu, Z, Koay, EJ, Ludmir, EB, Tran Cao, HS, Vauthey, JN, Newhook, TE, Tzeng, CD, Chun, YS, Mahvash, A, Metwalli, ZA, Habibollahi, P, Cox, V, Kang, H, Chatterjee, D, Kaseb, A, Javle, M, Lee, SS. Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). Journal of Clinical Oncology 42(3):458, 2024. e-Pub 2024.
- Dayyani, F, Baretti, M, Lee, SS, He, AR, Kim, RD, Lin, BS, Enzler, T, Al Hallak, MN, Ulahannan, SV, Davis, SL, Burgoyne, AM, Tweardy, D, Harding, JJ, Kaseb, A, De Achaval, S, Alibhai, I, Kauh, J. A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma. Journal of Clinical Oncology 42(3):TPS577-TPS577, 2024. e-Pub 2024.
- Lapelusa, M, Chamseddine, SM, Xiao, L, Hasanov, E, Bhosale, PR, Abugabal, YI, Yavuz, BG, Yadav, SS, Cao, HS, Xu, L, Hu, Z, Lee, SS, Sakamuri, D, Curran, M, Jindal, S, Duda, GD, Sharma, P, Qayyum, A, Kaseb, A. Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
- Lee, SS, Almhanna, K, Sheth, RA, Pant, S, Kuban, JD, Maxwell, A, Witt, BJ, LaPorte, J, Hulstine, AM, Cox, B, Carvajal, R, White, RA, Weintraub, J, Davis, L, Hart, J, Knight, RD, Katz, SC, Javle, M. PERIO-02. Journal of Clinical Oncology 42(16_suppl):2622, 2024. e-Pub 2024.
- Fox, DA, Haro-Silerio, JI, Bhamidipati, D, Meric-Bernstam, F, Pant, S, Ross, JS, Hu, Z, Koay, EJ, Ludmir, EB, Tran Cao, HS, Tzeng, CD, Chun, YS, Vauthey, JN, Newhook, TE, Metwalli, ZA, Habibollahi, P, Cox, V, Kang, H, Javle, M, Lee, SS. Characterizing outcomes of ERBB2-amplified biliary tract cancer. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
- Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 11:455-461, 2024. e-Pub 2024. PMID: 38463542.
- Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H. Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nat Commun 14(1):7621, 2023. e-Pub 2023. PMID: 37993437.
- DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. e-Pub 2023. PMID: 37972659.
- Swords DS, Newhook TE, Tzeng CD, Massarweh NN, Chun YS, Lee S, Kaseb AO, Ghobrial M, Vauthey JN, Tran Cao HS. Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma. Ann Surg Oncol 30(12):7309-7318, 2023. e-Pub 2023. PMID: 37679537.
- Swords DS, Newhook TE, Tzeng CD, Massarweh NN, Chun YS, Lee S, Kaseb AO, Ghobrial M, Vauthey JN, Tran Cao HS. ASO Visual Abstract: Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma. Ann Surg Oncol. e-Pub 2023. PMID: 37782416.
- Lin YM, Fellman BM, Taiji R, Paolucci I, Silva JAM, Koay EJ, Avritscher R, Mahvash A, Holliday EB, Lee SS, Kaseb AO, Das P, Vauthey JN, Odisio BC. Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg 27(9):1867-1875, 2023. e-Pub 2023. PMID: 37268830.
- Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist 28(8):714-721, 2023. e-Pub 2023. PMID: 36952233.
- De B, Upadhyay R, Liao K, Kumala T, Shi C, Dodoo G, Abi Jaoude J, Corrigan KL, Manzar GS, Marqueen KE, Bernard V, Lee SS, Raghav KPS, Vauthey JN, Tzeng CD, Tran Cao HS, Lee G, Wo JY, Hong TS, Crane CH, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer 12(3):198-208, 2023. e-Pub 2023. PMID: 37593365.
- Ayabe RI, Paez-Arango N, Estrella JS, Newhook TE, Tzeng CD, Chun YS, Lee S, Javle M, Vauthey JN, Tran Cao HS. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes?. HPB (Oxford) 25(4):472-480, 2023. e-Pub 2023. PMID: 36781357.
- Dodoo GN, De B, Lee SS, Abi Jaoude J, Vauthey JN, Tzeng CD, Tran Cao HS, Katlowitz KA, Mandel JJ, Beckham TH, Minsky BD, Smith GL, Holliday EB, Koong AC, Das P, Taniguchi CM, Javle M, Koay EJ, Ludmir EB. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist, 2023. e-Pub 2023. PMID: 36715178.
- Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology 101(11):730-737, 2023. e-Pub 2023. PMID: 37467732.
- Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H. Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nature Communications, 2022. e-Pub 2022.
- Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget, 2022. e-Pub 2022.
- Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, Teschemaker A, Chopra I, Janjan N, Parasuraman S, Bekaii-Saab TS. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist, 2022. e-Pub 2022. PMID: 35972334.
- De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer 128(13):2529-2539, 2022. e-Pub 2022. PMID: 35417569.
- Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey JN, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel) 14(8), 2022. e-Pub 2022. PMID: 35454808.
- Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey JN, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel) , 2022. e-Pub 2022. PMID: 35454808.
- Lee S, Shroff R, Makawita S, Xiao L, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff R, Javle M. Phase II, Open-Labeled, Single Arm Study of Ramucirumab for Advanced, Pre-Treated Biliary Tract Cancer. Clinical Cancer Research, 2022. e-Pub 2022.
- Lee S, Jeong Y, Lee S, Sohn B, Choi GH, Kang CM, Lee WJ, Cheong JH, H-J J, Kaseb A, Robert L, Chun YH, J-S L. Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Communications, 2022. e-Pub 2022.
- Kaseb A, Hasanov E, Tran Cao H, Xiao L, J-N V, Lee S, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterology and Hepatology, 2022. e-Pub 2022.
- De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee S, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med, 2021. e-Pub 2021.
- Mohamed YI, Lee S, Xiao L, et al. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget, 2021. e-Pub 2021.
- Yavuz BG, Hasanov E, Lee S, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021. e-Pub 2021.
- Kaseb A, Kappadath SC, Lee S, Raghav K, Mohamed YI, Xiao L, Morris JF, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff R, Yao YC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90 Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021. e-Pub 2021.
- Demir T, Lee S, Kaseb AO. Systemic therapy of liver cancer. Advanced Cancer Research, 2021. e-Pub 2021.
- Mahalingam D, Chelis L, Nizamuddin I, Lee S, Kakolyris S, Halff G, Washburn K, Attwood K, Fahad I, Grigorieva J, Asmellash S, Meyer K, Oliveira C, Roder H, Roder J, Iyer R. Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrome-try-Based Test. Cancer, 2021. e-Pub 2021.
- Augustyna A, Reed VI, Ahmad N, Bhutani MS, Bloom ES, Bowers JR, Chronowsk GM, Das P, Holliday EB, Delclos ME, Huey RW, Koay EJ, Lee S, Nelson CL, Taniguchi CM, Koong AC, Chun SG. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clinical and Translational Radiation Oncology, 2021. e-Pub 2021.
- De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, Vauthey JN, Minsky BD, Herman JM, Das P, Smith GL, Taniguchi CM, Krishnan S, Crane CH, Grassberger C, Hong TS, Lin SH, Koong AC, Mohan R, Koay EJ. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. Journal of Hepatocellular Carcinoma 8:57-69, 2021. e-Pub 2021.
- Fountzilas C, Gupta M, Lee S, Krishnamurthi S, Estefan B, Wang K, Attwood K, Wilton J, Bies R, Bshara W, Iyer R. A multicenter phase Ib/II study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. British Journal of Cancer, 2020. e-Pub 2020.
- Hanif A, Lee S, Gupta M, Chander A, Kannisto ED, Punnanitinont A, Fenstermaker R, Ciesielski M, Attwood K, Qiu J, Yendamuri S, Iyer R. Exploring the role of survivin in neuroendocrine neoplasms. Oncotarget, 2020. e-Pub 2020.
- Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology 8(1):e1524695, 2019. e-Pub 2019. PMID: 30546965.
- Lee S, Loecher M, Iyer R. Immunomodulation in hepatocellular cancer. Journal of Gastrointestinal Oncology, 2018. e-Pub 2018.
- Lee S, Salehi I, Chary M, Schiano T, Mascarenhas JO. "Irony" of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. Transfus Apher Sci 55(1):105-8, 2016. e-Pub 2016. PMID: 27102761.
- Zaiem F, Alkhawam H, Lee S, Fabisevich M. Severe symptomatic babesiosis co-infection with Lyme disease. QJM, 2016. e-Pub 2016.
- Lee S, Khankhanian P, Salama C, Brown M, Lieber J. Human granulocytic anaplasmosis-induced pseudo-Pelger-Huët anomaly. International Journal of Hematology, 2015. e-Pub 2015.
- Lee S, Khankhanian P, Mascarenhas J. Corticosteroid-induced morphological changes in cells of the myeloid lineage. American Journal of Hematology, 2015. e-Pub 2015.
- Lee S. Lee S. Basophilic granules of eosinophils in myelodysplastic syndrome and hypereosinophilia have heterogeneously shattered electron dense cores. Bloodmed – British Society of Haematology, 2015. e-Pub 2015.
- Lee S, Khankhanian P, Mascarenhas J. Dysplastic changes of peripheral eosinophils in acute myeloid leukemia with myelodysplastic syndrome-related features. Blood, 2015. e-Pub 2015.
- Bakhsh U, Lee S, Ahmad S, Takher J, Pareek A, Syed U, Seashore J, Szemraj E. Should prostate cancer be considered as a differential diagnosis in patients with osteolytic bone lesions?. European Review for Medical and Pharmacological Sciences, 2015. e-Pub 2015.
- Lee S, Khankhanian P, Schneier A, Shiano T, Liu S, Machado O. Corticosteroid-treated cholestatic drug-induced liver injury complicated by miliary tuberculosis with associated adrenal insufficiency. European Review for Medical and Pharmacological Sciences, 2015. e-Pub 2015.
- Lee S, Chary M, Salehi I, Bansal R. Immune-mediated adalimumab-induced thrombocytopenia for the treatment of ulcerative colitis. International Journal of Pharmacy and Pharmaceutical Sciences, 2015. e-Pub 2015.
- Lee S, Yang Y, Fishman D, Banaszak Holl MM, Hong S. Epithelial-mesenchymal transition enhances nano-scale actin filament dynamics of ovarian cancer cells. Journal of Physical Chemistry B, 2013. e-Pub 2013.
- Lee S, Zeiger A, Maloney JM, Kotecki M, Van Vliet KJ, Herman IM. Pericyte actomyosin-mediated contraction at the cell-material interface can modulate the microvascular niche. Journal of Physics-Condensed Matter, 2010. e-Pub 2010.
- Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, Loop 6, binds IGF-IR: a novel cell surface receptor for TIMP-2, Loop 6 of TIMP-2 binds IGF-IR. Journal of Biological Chemistry, 2010. e-Pub 2010.
- Chen AA, Khetani SR, Lee S, Bhatia SN, Van Vliet KJ. Modulation of hepatocyte phenotype in vitro via chemomechanical tuning of polyelectrolyte multilayers. Biomaterials, 2009. e-Pub 2009.
- Hwang DK, Oakey J, Toner M, Arthur JA, Anseth KS, Lee S, Zeiger A, Van Vliet KJ, Doyle PS. Stop-flow lithography for the production of shape-evolving degradable microgel particles. Journal of the American Chemical Society, 2009. e-Pub 2009.
- Walton EB, Lee S, Van Vliet KJ. Extending Bell's model: how force transducer stiffness alters measured unbinding forces and kinetics of molecular complexes. Biophysical Journal, 2008. e-Pub 2008.
- Lee S, Mandic J, Van Vliet KJ. Chemomechanical mapping of ligand-receptor binding kinetics on cells. Proceedings of the National Academy of Sciences of USA, 2007. e-Pub 2007.
Review Articles
- Adesoye, T, Ileana Dumbrava, EE, Raghav, KS, Sahin, AA, Chen, H, Lee, SS, Javle, M, Pant, S, Alhalabi, O, Le, X, Valero, V, Pohlmann, PR, Meric-Bernstam, F. Advances in Targeting HER2 across Cancer Subtypes. Clinical Cancer Research 32(2):260-290, 2026. e-Pub 2026. PMID: 41283902.
- Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835569.
- Ahmed Z, Lee SS, Victor DW, Kodali S. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 10:1911-1922, 2023. e-Pub 2023. PMID: 37915617.
Other Articles
- Yim SY, Lee SH, Baek SW, Sohn B, Jeong YS, Kang SH, Park K, Park H, Lee SS, Kaseb AO, Park YN, Leem SH, Curran MA, Kim JH, Lee JS Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]. Clin Mol Hepatol 31(2):669-670, 2025. PMID: 40012401.
Abstracts
- Cham BB, Lee SS. Clinical outcomes and genomic evolution of FGFR2 fusions/rearrangements in intrahepatic cholangiocarcinoma. Cancer Research 82(12), 2022. e-Pub 2022.
- Lee HS, Kim K, Kang G, Jung KH, Kaseb A, Lee SS. Quantitative analysis of spatial distribution of lymphocytes in hepatocellular carcinoma: A biomarker correlated with survival and gene expression in cancer immune system. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Lee HS, Kim K, Kang G, Jung KH, Lee SS. Spatial distribution of immune cells as quantitative prognosis indicator in hepatocellular carcinoma. Cancer Research 82(12), 2022. e-Pub 2022.
- Park J, Kim K, Lee HS, Kang G, Jung KH, Kaseb AO, Lee S. Impact of cell density in lymphocyte-rich areas in the tumor microenvironment on prognosis and gene expression landscape in hepatocellular carcinoma. Journal of Clinical Oncology, 2021. e-Pub 2021.
- Lee S, Tran Cao HS, Tzeng CD, Metwalli Z, Koay E, Ludmir EB, Chun YS, Chun SG, Javle M. Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers. Journal of Clinical Oncology, 2021. e-Pub 2021.
- Kim Y, Kim K, Park J, Park H, Jung K, Lee SS. Deep learning-based analysis of tissue segmentation in histopathology images of colorectal cancer. Cancer Research, 2020. e-Pub 2020.
- Mohamed YI, Qayyum A, Hassan M, Xiao L, Duda DG, Hatia R, Lee S, Wolff RA, Morris J, Altameemi L, Yao JC, Amin HM, Kaseb A. IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Mohamed YI, Qayyum A, Hassan M, Xiao L, Duda DG, Hatia R, Lee S, Wolff RA, Morris J, Altameemi L, Yao JC, Amin HM, Kaseb A. Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Lee S, Abugabal Y, Qayyum A, Hassan M, Xiao L, Duda D, Hatia R, Wolff R, Morris J, Altameemi L, Yao J, Amin H, Kaseb A. The role of ALBI and IGF-CTP score in refining prognostication of HCC. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Kaseb A, Tran Cao H, Mohamed YI, Qayyum A, Vence LM, Blando JM, Singh S, Lee S, Raghav K, Altameemi L, Rashid A, J-N V, Carter K, C-W T, Chun SH, Yao JC, Wolff RA, Allison JP, Sharma P. Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Lee SH, Lee S, J-S L. Molecular validation of the 8th edition AJCC cancer staging system in patients with resected pancreatic cancer: Proposal of integrative translational staging system. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Lee S, Abugabal Y, Baird A, Dolan J, Furqan F, Kaseb A. Risk score and prognostication modeling based on mRNA expressivity in the tumor microenvironment of hepatocellular carcinoma. Journal of Clinical Oncology 38:no. 15_suppl, 2020. e-Pub 2020.
- Abdou Y, Baird A, Dolan J, Lee S, Park S, Lee S. Prognostication model based on genomic expression in the tumor microenvironment of ER-positive, HER2-negative stage III breast cancer via machine learning. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Abugabal Y, Qayyum A, Hassan M, Xiao L, Duda D, Hatia R, Lee S, Wolff R, Pestana R, Morris J, Yao J, Amin H, Kaseb A. IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Abdou Y, Baird A, Dolan J, Lee S, Park S, and Lee S. Machine learning-assisted prognostication based on genomic expression in the tumour microenvironment of estrogen receptor positive and HER2 negative breast cancer. Annals of Oncology, 2019. e-Pub 2019.
- Lee S, Jerez J, Elkhanany A, Farrukh F, Baird A, Baird S, Dolan J. Risk score and prognosis modeling based on mRNA expressivity in the tumor microenvironment of GI cancers. Journal of Clinical Oncology, 2019. e-Pub 2019.
- Lee S, Kwon SJ, Lee DE, Lee S, Baird A, Park S, Dolan J, George S. Modeling of prognostication and differential genomic expression in the tumor microenvironment of clear cell renal cell carcinoma. Journal of Clinical Oncology, 2019. e-Pub 2019.
- Lee S, Attwood, K, Roder H, Asmellash S, Meyer K, Kakolyris S, Oliveira C, Roder J, Grigorieva J, Chelis L, Iyer R, Mahalingam D. An independent validation of a screening test using mass spectrometry for detection of hepatocellular carcinoma. Cancer Research, 2019. e-Pub 2019.
- Lee S, Kim JC, Lee S, Dolan J, and Baird A. Automated mapping and analysis of stromal cells in tumor microenvironment in pancreatic adenocarcinoma and cholangiocarcinoma using deep learning. Cancer Research, 2018. e-Pub 2018.
- Lee S, Kim JC, Dolan J, Baird A, A. Automation of quantifying and mapping of stromal and malignant cells in pancreatic adenocarcinoma using deep learning. Journal of Clinical Oncology, 2018. e-Pub 2018.
- Lee S, Chary M, Mascarenhas J. Paraneoplastic orthostatic hypotension associated with acute myeloid leukemia with trisomy 8. Journal of Investigative Medicine, 2015. e-Pub 2015.
- Lee S, Khankhanian P, Salama C, Brown M, Lieber J. Pseudo-Pelger-Huët anomaly and granulcytic dysplasia associated with human granulocytic anaplasmosis. Journal of Investigative Medicine, 2015. e-Pub 2015.
- Lee S, Salehi I, Chary M, Schiano T, Mascarenhas J. Irony of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer, 2015. e-Pub 2015.
- Lee S, Schneier A, Petersen B, Gabrilove J, Lin J. Fulminant hepatic failure from hemophagocytic lymphohistiocytosis secondary to hepatosplenic T-cell lymphoma, mimicking Chinese herb-induced liver failure. Pediatric Blood & Cancer, 2015. e-Pub 2015.
- Lee S, Schneier A, Petersen B, Gabrilove J, Lin J. Fulminant hepatic failure from hemophagocytic lymphohistiocytosis secondary to hepatosplenic T-cell lymphoma, mimicking Chinese herb-induced liver failure. Journal of Investigative Medicine, 2015. e-Pub 2015.
- Lee S, Chary M, Fadi S, Petersen B, Lin J. Evolution of peripheral blood smear and lymph node histology in miliary tuberculosis. Journal of Investigative Medicine, 2015. e-Pub 2015.
- Lee S, Khankhanian P, Schneier A, Shiano T, Liu S, Machado O. Cholestatic drug-induced liver injury treated with corticosteroid in a patient with miliary tuberculosis and associated adrenal insufficiency. Journal of Investigative Medicine, 2015. e-Pub 2015.
- Lee S, Khankhanian P, Mascarenhas J. Corticosteroid-induced morphological changes in cells of the myeloid lineage. Journal of Investigative Medicine, 2015. e-Pub 2015.
- Lee S, Chary M, Mascarenhas J. Irony of transfusional support for refractory anemia in hemophagocytic lymphohistiocytosis. Journal of Investigative Medicine, 2015. e-Pub 2015.
Book Chapters
- Lee, SS. Cholangiocarcinoma and liver transplantation, 41-49, 2024.
- Lee S, Zhang HC, Tran Cao HS, Kodali S, Kuban JD, Koay EJ, Avritscher R, Kaseb AO. Hepatocellular Carcinoma. In: The MD Anderson Manual of Medical Oncology, 4th edition. McGraw-Hill Education, 2021.
- Makawita S, Lee S, Chun YS, Roach MA, Koay EJ, Javle M. Biliary Tract Cancer. In: The MD Anderson Manual of Medical Oncology, 4th edition. McGraw-Hill Education, 2021.
- Demir T, Lee S, Kaseb AO. Systemic therapy of liver cancer, Mechanisms and Therapy of Liver Cancer. In: Advances in Cancer Research. Elsevier, 2021.
- Lee S, Loecher M, Puzanov I. Toxicities in immune checkpoint inhibitors. In: Immune Checkpoint Inhibitors in Cancer, 2018.
- Fountzilas C, Lee S, Iyer R, Boland P. Immune checkpoint inhibitors in gastrointestinal malignancies. In: Immune Checkpoint Inhibitors in Cancer, 2018.
- Lee S, Dy G. Immune checkpoint inhibitors in lung cancer. In: Immune Checkpoint Inhibitors in Cancer, 2018.
Patient Reviews
CV information above last modified March 24, 2026